SciSparc Ltd. (SPRC) AI Stock Analysis
SPRC AI stock analysis summary
AI ResearchSciSparc Ltd. (SPRC) is a clinical-stage pharmaceutical company focused on cannabinoid-based therapies for conditions such as Tourette syndrome, Alzheimer's disease, and epilepsy. For the trailing twelve months ended June 30, 2026, the company generated $679,000 in revenue with an operating margin of -1720.8%. The business maintains a market capitalization of $987,654 alongside net cash of $1.8M.
- Market cap
- $987,654
- Revenue (TTM)
- $679,000
- P/E
- 0.0x
- 1Y return
- -95.2% S&P 500 16.8%
- Avg. target
- —
Bull case
- SciSparc ended the quarter on June 30, 2026, with a positive net cash balance of $1.8M, supported by $4.4M in cash and short-term investments.
- The stock trades at a price-to-book ratio of 0.7x and a price-to-sales ratio of 1.5x, which compares favorably to the US-listed Healthcare median price-to-sales multiple of 4.1x.
- SciSparc demonstrated multi-year expansion earlier in the decade, producing a 5-year revenue CAGR of 9.3% from FY2020 through FY2025.
Bear case
- Net losses widened substantially in FY2025 to -$12.2M, down from -$6.3M in FY2024.
- Revenue in the latest quarter ended June 30, 2026, decreased by 38.4% year-over-year, following an annual decline of 34.5% in FY2025.
- SciSparc's share price dropped 95.2% over the trailing 1-year period, closing at $1.70 against its 52-week high of $40.41.
What SciSparc does
SciSparc Ltd., formerly known as Therapix Biosciences Ltd., is a clinical-stage biotechnology company based in Tel Aviv-Yafo, Israel, that develops therapeutic treatments utilizing cannabinoid molecules. Its primary drug development pipeline includes SCI-110 for Tourette syndrome, obstructive sleep apnea, and Alzheimer's disease-related agitation. It also develops SCI-160 for pain management and SCI-210 for autism spectrum disorder and epilepsy. The company engages in partnerships, collaborating with Procaps for the commercial production of SCI-110 and CannAmide, and working alongside the Sheba Fund for Health Services and Research as well as The Israeli Medical Center for Alzheimer's.
Growth and profitability
SciSparc delivered a 5-year revenue CAGR of 9.3% between FY2020 and FY2025, but top-line performance has contracted in recent years. Revenue climbed from $1.1M in FY2021 to $2.9M in FY2023, before falling to $1.3M in FY2024 and $856,000 in FY2025. Gross margin stood at 73.7% in FY2025, while operating margin deteriorated to -1022.1%, yielding a net income of -$12.2M. Over the trailing twelve months, revenue totaled $679,000 with a profit margin of 0.0% and an operating margin of -1720.8%. For the latest quarter ended June 30, 2026, quarterly revenue growth declined 38.4% year-over-year.
Balance sheet and cash flow
As of the quarter ended June 30, 2026, SciSparc held $4.4M in cash and short-term investments against total debt of $2.7M, resulting in net cash of $1.8M. Total assets reached $18.5M compared to shareholders' equity of $3.9M, with a current ratio of 0.87 and a debt-to-equity ratio of 0.68. The company has consumed cash in its operations, generating -$4.1M in operating cash flow and free cash flow in FY2025. Additionally, the company's share count change over 5 years is -82.1%.
Valuation and performance
SciSparc trades at a market capitalization of $987,654 and an enterprise value of -$1.3M. The stock has a price-to-sales multiple of 1.5x, which sits below the 4.1x median of its US-listed Healthcare peers. Its price-to-book ratio is 0.7x, while trailing P/E is 0.0x compared to the peer median of 24.6x. The shares closed at $1.70 on October 16, 2026, having fallen 95.2% over the past 1 year, compared to a 16.8% return for the S&P 500 (SPY).
What analysts expect
SciSparc has limited Wall Street analyst tracking, with no published consensus rating counts, average price targets, or forward fiscal year revenue estimates available. Regarding historical execution against analyst benchmarks, SciSparc recorded 0 EPS beats over the last 4 quarters. The company's trailing twelve-month diluted earnings per share was reported at $248.24. Institutional investors hold 9.3% of the outstanding shares, while insiders hold 0.0% and short interest accounts for 2.0% of the float.
Key risks and what to watch
- SciSparc generated negative free cash flow of -$4.1M in FY2025, which puts ongoing pressure on its $4.4M cash and short-term investment reserves.
- The company's current ratio of 0.87 indicates that short-term obligations exceed current assets as of June 30, 2026.
- Operating margins deteriorated to -1720.8% over the trailing twelve months, reflecting significant overhead relative to its $679,000 in TTM revenue.
- With a stock beta of 2.55, the shares exhibit high volatility relative to broader market benchmarks.
AI-generated research summary. Written with AI from Quotelinks data as of October 16, 2026 and checked so every figure matches that data. For information only, not investment advice. Disclaimer
About this SPRC AI stock analysis
This page is an AI-written research summary of SciSparc Ltd. (SPRC). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.
Related: SPRC income statement, SPRC balance sheet, SPRC key metrics, SPRC chart. See the SPRC stock overview for the latest quote and news.
SPRC AI stock analysis FAQ
What does SciSparc Ltd. do?
SciSparc Ltd. is a clinical-stage biotechnology company developing cannabinoid-based therapies, including SCI-110 for Tourette syndrome and Alzheimer's agitation, SCI-160 for pain, and SCI-210 for autism spectrum disorder and epilepsy.
What was SciSparc's revenue in the most recent fiscal year?
In FY2025, SciSparc reported annual revenue of $856,000, which represented a 34.5% decline compared to FY2024.
Does SciSparc pay a dividend?
SciSparc does not pay a dividend.
How much cash and debt does SciSparc have?
As of June 30, 2026, SciSparc held $4.4M in cash and short-term investments alongside total debt of $2.7M, providing net cash of $1.8M.
How has SPRC stock performed over the past year?
Over the trailing 1-year period ending October 16, 2026, SPRC fell 95.2% to close at $1.70, while the S&P 500 gained 16.8%.